SIGMAR1 and malignant colon neoplasm: In fact, knockdown of SigmaR1 or use of the ligand igmesine, which inhibits SigmaR1, abolished the SK3/Orai1 interplay of channels in cholesterol-rich nanodomains in breast and colon cancer cells [294].